Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis

Somatic activating ARAF mutations in Langerhans cell histiocytosis

(2014) D. S. Nelson et al.   BLOOD

Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms

(2014) P. Lundberg et al.   BLOOD

Launching genomics into the cloud: deployment of Mercury, a next generation sequence analysis pipeline

(2014) Jeffrey G Reid et al.   BMC BIOINFORMATICS

BRAF-V600Eexpression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups

(2014) Marie-Luise Berres et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Genomic Sequencing for Cancer Diagnosis and Therapy

(2013) Linghua Wang et al.   Annual Review of Medicine

Detection of an NRAS mutation in Erdheim-Chester disease

(2013) E. L. Diamond et al.   BLOOD

Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis

(2013) H. Gadner et al.   BLOOD

Oncogenic ERBB3 Mutations in Human Cancers

(2013) Bijay S. Jaiswal et al.   CANCER CELL

Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma

(2013) David T W Jones et al.   NATURE GENETICS

High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses

(2012) J. Haroche et al.   BLOOD

BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis

(2012) F. Sahm et al.   BLOOD

MEK genomics in development and disease

(2012) J. L. Bromberg-White et al.   Briefings in Functional Genomics

A Landscape of Driver Mutations in Melanoma

(2012) Eran Hodis et al.   CELL

Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing

(2012) Marcin Imielinski et al.   CELL

Identification of the V600D mutation in Exon 15 of theBRAFoncogene in congenital, benign langerhans cell histiocytosis

(2012) Rina Kansal et al.   GENES CHROMOSOMES & CANCER

Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by NRAS or MEK Mutations

(2012) J. G. Greger et al.   MOLECULAR CANCER THERAPEUTICS

B-RAF Mutant Alleles Associated with Langerhans Cell Histiocytosis, a Granulomatous Pediatric Disease

(2012) Takeshi Satoh et al.   PLoS One

Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma

(2011) Sergey I Nikolaev et al.   NATURE GENETICS

Benchmarking of Mutation Diagnostics in Clinical Lung Cancer Specimens

(2011) Silvia Querings et al.   PLoS One

Resistance to MEK Inhibitors: Should We Co-Target Upstream?

(2011) P. I. Poulikakos et al.   Science Signaling

High Frequency of PIK3R1 and PIK3R2 Mutations in Endometrial Cancer Elucidates a Novel Mechanism for Regulation of PTEN Protein Stability

(2011) Lydia W.T. Cheung et al.   Cancer Discovery

Targeted enrichment beyond the consensus coding DNA sequence exome reveals exons with higher variant densities

(2011) Matthew N Bainbridge et al.   GENOME BIOLOGY

Recurrent BRAF mutations in Langerhans cell histiocytosis

(2010) G. Badalian-Very et al.   BLOOD

Cell-Specific Gene Expression in Langerhans Cell Histiocytosis Lesions Reveals a Distinct Profile Compared with Epidermal Langerhans Cells

(2010) C. E. Allen et al.   JOURNAL OF IMMUNOLOGY

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

(2010) Poulikos I. Poulikakos et al.   NATURE

COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer

(2010) S. A. Forbes et al.   NUCLEIC ACIDS RESEARCH

The cancer genome

(2009) Michael R. Stratton et al.   NATURE

No genomic aberrations in Langerhans cell histiocytosis as assessed by diverse molecular technologies

(2008) Cristiana E. T. da Costa et al.   GENES CHROMOSOMES & CANCER

Juvenile myelomonocytic leukemia: A report from the 2nd International JMML Symposium

(2008) Rebecca J. Chan et al.   LEUKEMIA RESEARCH